Drug Trial Radar · NCT03294577
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
Last checked: Nov 19, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
221
Actual
Start
Oct 23, 2019
Primary completion
Sep 25, 2020
Study completion Sep 25, 2025
Sponsor
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.
Conditions
- Chemotherapy-induced Neutropenia
Interventions
PegfilgrastimDrug
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
PlinabulinDrug
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
D5W PlaceboOther
Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
Docetaxel, doxorubicin, and cyclophosphamide (TAC)Drug
Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with Duration of Severe Neutropenia (DSN) =0Time frame: Duration of Grade 4 neutropenia assessed during the first cycle (21 days)
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
No. 1 Banshandong Road
Hangzhou, Gongshu District, China
Cancer Center of Guangzhou Medical University
Guangzhou, Guangdong, China
Cancer Center of Guangzhou Medical University Breast Oncology
Guangzhou, Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, Harbin, China
Fourth Hospital of Hebei Medical University Breast cancer department
Shijiazhuang, Hebei, China
China-Japan Union Hospital of Jilin University Tumor department of Hematology
Changchun, Jilin, China
Liaoning Cancer Hospital & Institute
Shenyang, Shenyang, China
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department
Dnipro, Ukraine
Prykarpatskiy Regional Oncological Center
Ivano-Frankivsk, Ukraine
Regional Clinical Oncology Center
Kharkiv, Ukraine
V.T. Zaycev Institute
Kharkiv, Ukraine
Kirovograd Regional Oncological Center
Kropyvnytskyi, Ukraine
Public Institution Kryvyi Rih Oncology Center
Krutyi Bereh, Ukraine
Hemotherapy Department
Kyiv, Ukraine
Kyiv City Clinical Oncological Center
Kyiv, Ukraine
Lviv State Oncological Regional
Lviv, Ukraine
Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho
Odesa, Ukraine
Zakarpattia Regional Clinical Oncology Center
Uzhhorod, Ukraine
Vinnytsya Regional Clinical Oncology Dispensary
Vinnytsia, Ukraine
Zaporizhia Regional Clinical Oncology Dispensary
Zaporizhzhya, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.